据证券之星公开数据整理，近期欧林生物（688319）发布2025年中报。根据财报显示，欧林生物营收净 利润同比双双增长。截至本报告期末，公司营业总收入3.06亿元，同比上升35.17%，归母净利润 1319.69万元，同比上升147.22%。按单季度数据看，第二季度营业总收入2.18亿元，同比上升40.44%， 第二季度归母净利润2027.08万元，同比上升1139.49%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率93.17%，同比减1.47%，净利率4.33%，同比增 131.86%，销售费用、管理费用、财务费用总计1.85亿元，三费占营收比60.59%，同比减11.73%，每股 净资产2.28元，同比增5.07%，每股经营性现金流-0.05元，同比增65.85%，每股收益0.03元，同比增 147.31% 证券之星价投圈财报分析工具显示： 商业模式：公司业绩主要依靠研发及营销驱动。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示： 建议关注公司现金流状况（货币资金/流动负债仅为42.39%、近3年经营性现金流均值/流动负债仅为 0.68%） 建议关注公司债务状况（有息资产负债率已达21. ...

Group 1 - The core viewpoint of the news is that Dabo Medical (002901.SZ) has reported its semi-annual results for 2025, highlighting significant institutional investment in the company [1] - As of August 21, 2025, a total of 14 institutional investors hold shares in Dabo Medical, with a combined holding of 192 million shares, representing 46.36% of the total share capital [1] - The top ten institutional investors account for 46.23% of the total shares, with a decrease of 1.08 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund, Southern CSI 1000 ETF, increased its holdings slightly, while six new public funds were disclosed, including Dachen Multi-Strategy Mixed (LOF) A and Dachen Quality Medical Stock A [2] - Three public funds were not disclosed in the current period compared to the previous quarter, including Huabao CSI Medical ETF and Fuyong Medical Health Mixed Fund A [2] - Regarding foreign investment, one foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.46% compared to the previous period [2]